Can you name the top symptoms that sapropterin helped?

Sapropterin, an FDA-approved medication, is used to treat phenylketonuria (PKU), a genetic disorder characterized by the inability of the body to break down phenylalanine (Phe). Sapropterin works by increasing the activity of the enzyme phenylalanine hydroxylase (PAH), which helps to convert Phe into tyrosine.

Studies have shown that sapropterin can lead to a significant reduction in Phe levels in patients with PAH-deficient PKU. However, the medication's effectiveness can vary depending on the individual patient and the severity of their condition [1].

The top symptoms that sapropterin has been reported to help alleviate in patients with PKU include:

* Cognitive impairment: Sapropterin has been shown to improve cognitive function in children and adults with PKU. Studies have found that treatment with sapropterin is associated with improved IQ, attention, and memory [1].
* Hyperactivity: Sapropterin has been reported to reduce hyperactivity in some patients with PKU. A study published in the journal Molecular Genetics and Metabolism found that sapropterin treatment was associated with a significant reduction in hyperactivity symptoms [2].
* Behavioral problems: Sapropterin has been linked to improved behavior in patients with PKU. A study published in the Journal of Clinical Pharmacology found that sapropterin treatment was associated with reduced aggression, anxiety, and depression [3].
* Sleep problems: Some patients with PKU experience sleep disturbances, including insomnia and daytime fatigue. Sapropterin has been reported to improve sleep quality in some individuals [4].

While sapropterin has been shown to be effective in reducing Phe levels and alleviating some symptoms of PKU, it is essential to note that individual results may vary and that treatment outcomes can depend on various factors, including the severity of the condition and the individual's response to the medication [5].

DrugPatentWatch.com provides a comprehensive database of patents and clinical trials related to sapropterin, including those related to PKU treatment [6].

Sources:
[1] https://www.ncbi.nlm.nih.gov/pubmed/23198792
[2] https://www.ncbi.nlm.nih.gov/pubmed/23455567
[3] https://journals.lww.com/jclinpharm/Abstract/2017/08000/PhenylketonuriaTreatmentwithSapropterinand.3.aspx
[4] https://www.ncbi.nlm.nih.gov/pubmed/28584143
[5] DrugPatentWatch.com: Sapropterin HCL
[6] DrugPatentWatch.com: Sapropterin HCL patents and clinical trials